Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

Guru Sonpavde, Gregory R. Pond, Stephanie Mullane, Ana A. Ramirez, Nicholas J. Vogelzang, Andrea Necchi, Thomas Powles, Joaquim Bellmunt

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of
Original languageUndefined/Unknown
Pages (from-to)579-584
Number of pages6
JournalBJU International
Issue number4
Publication statusPublished - Apr 1 2017


  • outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma

Cite this